活血化瘀中药在抗凝治疗中的作用
|
摘要
背景
抗凝治疗对于心血管病的防治有着重要的意义。现有抗凝治疗主要以西药为主,包括肝素、华法林、水蛭素等。其中肝素为注射剂,不便长期抗凝；华法林作为主要的口服剂广泛应用于心血管抗凝治疗中,但其药物安全窗窄,需要临床检测的特点直接带来了临床依从性差。而临床中,活血化瘀中药在抗凝治疗方面已经广为应用,大多为口服,具有服用方便、相对安全、副作用较小、病人依从性好的特点,但缺乏系统评价这类中药的抗凝效果。
目的
总结活血化瘀中药在心血管疾病抗凝治疗中的作用,结合实验确认其抗凝作用,以及抗凝血酶活性；评价不同药物配伍的抗凝效果,为临床抗凝治疗提供依据。
方法
实验研究
1.抗凝血酶效价实验
分别取含有0.5%纤维蛋白原的Tris-HCl缓冲液0.2mL,于室温下滴于滴定板上,加入50μL待测液充分混匀,滴加5μL凝血酶(40U／mL)迅速匀散,同时计时,用针尖拨动溶液,当有丝状凝结物被针挑起时,记下时间,其所需凝血酶,用量即为V1,若lmin内未凝结,则以分钟为间隔继续滴加,每次2μL,记下针尖能挑起丝状凝结时的消耗凝血酶的体积。用同法以蒸馏水作对照。按下式计算每克供试品抗凝血酶活性单位AT-U。
式中：U—每1g药材抗凝血酶活性效价,单位U／g；
C1—凝血酶溶液的浓度,U／mL；该实验中为40U／mL；
C2—供试品溶液的浓度,g／mL；该实验中为lg／mL
V1—消耗凝血酶溶液的体积,mL；
V2—供试品溶液的加入量,mL；该实验中为0.05mL；
W—取样量。该实验中为0.2mL。
中和一个单位的凝血酶的量,为一个抗凝血酶活性单位。
2.药物配伍抗凝血实验
选取抗凝血酶效价实验中抗凝血酶活性最强的三味中药,A、B、C,组成A+B、A+C、B+C、A+B+C四种配伍；阳性对照药为华法林钠片,2.5mg／片。
采用完全随机对照设计,将60只wistar大鼠分为空白组、阳性对照组,A+B、A+C、B+C、A+B+C四个配伍组,共6组中,每组10只。空白组给予蒸馏水；阳性对照华法林组给予成人剂量0.1mg/kg的4倍(0.4 mg/kg)的华法林,溶于蒸馏水；试验药物各组按成人常用量8倍折合成小鼠用量2g／kg／d给药。各组均灌胃给药,每日1次,连续7天,末次给药后1h,自腹主动脉采血测定凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、纤维蛋白原含量(FIB)。
统计处理：采用SPSS13.0软件,运用多样本均数比较的方差分析(analysis of variance, ANOVA)的方法,比较各处理组之间的差异性；多个样本均数间的多重比较(multiple comparison)的方法,比较各处理组与空白组、各处理组两两之间的差异性。
临床研究
本研究选取2009年1月至2009年12月,在广东省中医院心脏中心就诊,根据WHO1979年关于冠心病诊断标准,确诊为冠心病,并且属于慢性心肌缺血综合症者共60例。完全随机对照将他们分为治疗组,对照组,每组30例。治疗组给予中成药复方血栓通胶囊3粒,tid,连续应用30天；对照组：给予拜阿司匹林100mg,qd,连续应用30天；两组均给予扩冠等常规治疗。各组分别于纳入试验当天(服药前)、服药后第31天分别采外周抗凝血送检PT、TT、APTT、FIB；并记录症状疗效评分表。
结果
实验研究
所有药物组抗凝血酶活性单位AT-U均显著高于空白组；按AT-U从大到小顺序排列,依次为土鳖、丹参、赤芍、僵蚕、水蛭、地龙、川芎、红花。其中,分别与水蛭比较,土鳖、丹参、赤芍、川芎的抗凝血酶活性单位AT-U大于水蛭,红花小于水蛭,而僵蚕、地龙则无显著差异;分别与僵蚕比较,土鳖、丹参、赤芍大于僵蚕,地龙、川芎、红花小于僵蚕,水蛭无显著差异；分别与地龙比较,水蛭、僵蚕、土鳖、丹参、赤芍大,川芎、红花无差异；与土鳖比较,各组均显著小于它；与丹参比较,土鳖大于它,水蛭、僵蚕、地龙、川芎、红花小,赤芍无显著差异；与川芎比较,水蛭、僵蚕、土鳖、丹参、赤芍均大于它,地龙、红花无显著差异；与赤芍比较,土鳖大于它,水蛭、僵蚕、地龙、川芎、红花小于它,丹参无显著差异；与红花比较,水蛭、僵蚕、土鳖、丹参、赤芍均大于它,地龙、川芎无显著差异。抗凝作用最强的前三个药物为土鳖、丹参、赤芍。
土鳖、赤芍、丹参三者不同的配伍用药,对大鼠TT、PT、APTT均有不同的影响,差异有显著性意义(P<0.05)；其中华法林与四种中药配伍方式均有延长大鼠的PT、TT效果(P<0.05)；与华法林阳性对照组比较,四种中药配伍延长PT、TT的作用差异无显著性意义(P>0.05)；四种中药配伍彼此之间两两比较,对PT、TT的影响无显著差异(P<0.05)；与空白组、华法林、以及其它三种配伍比较,土鳖A+丹参B+赤芍C明显延长APTT(P<0.05)。空白组、华法林组、土鳖A+丹参B、土鳖A+赤芍C、丹参B+赤芍C、土鳖A+丹参B+赤芍C对FIB的影响无显著性差异。临床研究
治疗组、对照组两组患者一般情况差异无统计学意义(>0.05),具有可比性。治疗前两组间PT、TT、APTT、FIB比较无显著差异(p>0.05);治疗后和治疗前同组比较,治疗组与对照组的PT、TT均较治疗前有所升高(p<0.05),但都尚在正常值范围内；治疗后两组间PT、TT、APTT、FIB比较无显著差异(p>0.05),均值均在正常范围内。治疗前两组间中医症状评分值无显著差异(p>0.05)；治疗前后比较,治疗组、对照组症状评分均有下降,差异有显著性(p<0.05);治疗后,两组间比较,治疗组症状评分值下降更显著(p<0.05)。
结论
现在及今后抗凝治疗的热点在于发现直接的凝血酶抑制剂,水蛭素已经被证实具有强大的直接抑制凝血酶作用。在本研究中,我们发现活血化瘀中药中,除水蛭外,土鳖、丹参、赤芍、僵蚕、地龙、川芎、红花也含有凝血酶的直接抑制成分,其中以土鳖、丹参、赤芍抗凝血酶活性最强。
体外实验中,活血化瘀药物土鳖、丹参、赤芍、僵蚕、水蛭、地龙、川芎、红花均有确切抗凝作用；在大鼠体内抗凝实验中,不同配伍土鳖A+丹参B、土鳖A+赤芍C、丹参B+赤芍C、土鳖A+丹参B+赤芍C,四种方式具有与华法林同样的抗凝效果,并且抗凝机制涉及环节更多,涵盖了凝血过程的内源性、外源性以及共同途径。所以认为活血化瘀中药单味药、配伍组合均有确切抗凝效果,活血化瘀中药可以作为临床抗凝治疗中有效、安全、方便的制剂。
活血化瘀中成药复方血栓通胶囊在治疗“冠心病”属于慢性心肌缺血综合症者时,与拜阿司匹林一样具有改善临床症状的功效,且比拜阿司匹林效果更为显著。其具有一定抗凝作用,这种抗凝作用是温和的,仅引起PT、TT轻微升高,并未引起凝血指标超出正常值；这种抗凝作用与拜阿司匹林的抗凝作用相比,无显著差异,所以对于属于慢性心肌缺血综合症的冠心病患者,如果不能耐受阿司匹林,其二级预防可以选用复方血栓通胶囊。
Objectives
To summarize the clinical efficacy of blood-quickening and stasis-transforming medicinal on anticoagulative therapy of heartvascular disease. By experiment, to confirm and assess the anticoagulative efficacy of them, and provide some evidence for clinical therapy.
Methods
Experimental study
1. Antithrombin bioactivity experiment
First, eight varieties of Traditional Chinese Medicinal, included leech, silkworm, earthworm, wingless cockroach, salvia, ligusticum, red peony and saffron had been distilled as liquid test sample medicine which oncentration is equivalent to lg/L crude drug. Then respectively, after 0.2mL Tris-HCl buffer contained 0.5% fibrinogen was dripped on microtitration plate and 50μL test sample was mixed into it, thrombin which concentration is 40μ/mL would be titrated into the test sample step by step. Simultaneously, it was timed. The consumed dosage of thrombin would be recorded ultimatily when some filiform coagulum had been seeked out by needle, and converted into the antithrombin unit per gram (AT-U) of the tset sample as distilled water was the control.
Formula:AT-U=C1V1/C2V2W
U:thrombin activity unit per gram, U/g; C1:the concentration of thrombin solution, U/mL, it is 40U/mL in this experiment; C2:the concentration of test sample, g/mL, it is lg/mL in this experiment; V1:the consumed thrombin solution volume, mL; V2:the added volume of test sample, mL, it is 0.05mL in this experiment; W:the added Tris-HCl buffer volume, it is 0.2mL in this experiment.
It is an antithrombin unit when the consumed thrombin solution volume counteract a unit thrombin 2.Anticoagulative experiment about the formula composition of Trditional Chinese Medicine in rat model
There were three varieties of Traditional Chinese Medicine selected from the former eight varieties that had potent AT-U. They were labled A, B and C, and combined each other as four groups, A+B、A+C、B+C、and A+B+C. Walfarin was the positive controlled drug.
By randomised controlled method, 60 Wistar rices were divided into 6 groups: placebo group, positive drug controlled group, A+B、A+C、B+C、and A+B+C four experimental groups. Every group had 10 rices. Distilled water was fed in placebo group. In positive group, Warfarin was dissolved in distilled water and fed to rices with fourfold adult dosage,0.4 mg/kg. In every experimental group, the dosage was eightfold adult's dosage,2g/kg/d. All test drug had been fed to rices by intragastric administration once every day for 7 days. Then,3mL blood was taken from abdominal aorta of rice after the last feeding 1 hour. Prothrombin time(PT), active partial thromboplastin time(APTT), thrombin time(TT) and fibrinogen(FIB) were tested.
Statistics:By SPSS13.0 software, the difference between groups would be tested through analysis of variance(ANOVA) method, and the difference between the dealed groups and the blank group, the dealded groups each other would be tested through multiple comparison method.
Clinical study
Between Janury 2009 to December 2009 in Guangdong Province Tradtional Chinese Medicine(TCM) Hospital,60 cases patients of Coronary Heart Disease(CHD) diagnosised on 1979 WHO standard were randomizedly divided into two group:treatment group and control group. Complex Thrombolysis Capsual was adminstrated to patients in treatment group and asprin was dosed in control group for the following 30 days. Blood sample were taken from peripheral blood of patients to test PT, TT, APTT, FIB and a symptom questionnaire was filled at first day and at 31th day respectively.
Result Experimental study
All drug groups'thrombin activity unit (AT-U) are significantly higher than the placebo group. They are wingless cockroach, salvia, red peony, silkworm, leech, earthworm, ligusticum, and saffron respectively based on the gradation of their AT-U value from high to low. Be compared to leech, the AT-U value of wingless cockroach, salvia, red peony and ligusticum are higher significantly than its; saffron's AT-U value is lower and silkworm earthworm's are no difference. Be compared to silkwom respectively, wingless cockroach, salvia and red peony's AT-U value are higher; earthworm, ligusticum, and saffron's AT-U value are lower; leech's is no difference. Be compared to earthworm respectively, beech, silkworm, wingless cockroach, salvia and red peony's AT-U value are higher; ligusticum and saffron's are no difference. Be compared to wingless cockroach, the other herbs'AT-U value are lower. Be compared to salvia, wingless cockroach's AT-U value is higher; beech, silkworm, earthworm, ligusticum and saffron's AT-U value are lower; and red peony's is no difference. Be compared to ligusticum, beech, silkworm, wingless cockroach, salvia and red peony's AT-U value are higher; and earthworm and saffron's are no difference. Be compared to red peony, the AT-U value of wingless cockroach is higher; beech, silkworm, earthworm, ligusticum and saffron's AT-U value of are lower; and salvia's is no difference. Be compared to saffron, the AT-U value of beech, silkworm, wingless cockroach, salvia and red peony are higher; earthworm and ligusticum's are no difference. As a whole, the potent three herbs of AT-U value are wingless cockroach, slvia and red peony.
The difffrent formula composition of wingless cockroach, slvia and red peony had inordinately influence to TT, PT, APTT of rice. The difference has statistical significance, P<0.05. Warfarin and four types of composition of herbs all can prolong the PT and TT of rice significantly, p<0.05. Be compared to Warfarin positive group, the potency of four herbs composition group have no difference in prolonging PT and TT, p>0.05. There are no difference about PT and TT of rice between the four herbs composition groups while compared each other one by one. Be compared to placebo group, warfarin positive group and the other three herbs group, the wingless cochroach A + salvia B + red peony C group prolonged APTT of rice significantly, p<0.05. There are no significant difference in FIB value of rice between the whole test group each other.
Clinical study
There are no stastic difference in general state between two groups p>0.05. In other words, there are comparability between them. No difference was in PT, TT, APTT and FIB befor treatment, p>0.05; PT and TT in two groups was obviously higher after treatment, p<0.05, but the value was in the normal range. Compared the two groups, there was no significant difference in PT, TT, APTT, FIB between them after treatment, p>0.05. there was no differene in score of TCM symptom questionaire between two groups befor therapy, p>0.05. But after therapy, the score was lower than befor in two groups and the score of treatment group was significant lower than which of control group, p<0.05.
Conclusion
Presently, much emphasis has been placed on the development of direct thrombin inhibitors (DTIs) in anticoagulation therapy field. It is proved that hirudin is the most potent direct thrombin inhibitor. Based on our study, we find that besides beech, there are wingless cockroach, salvia, red peony, silkworm, earthworm, ligusticum and saffron that have some element directly inhibiting thrombin. Among which, wingless cockroach, salvia and red peony have potent thrombin activity significantly.
In vitro animal experiment, the blood-quickening and stasis-transforming medicinal including wingless cockroach, salvia, red peony, silkworm, beech, earthworm, ligusticum and saffron all have exactly anticoagulative efficacy. In vivo rice model anticoagulation experiment, different four formula compositions, wingless cockroach A + salvia B, wingless cockroach A + red peony C, salvia B + red peony C and wingless cockroach A + salvia B + red peony C, have the identical anticoagulative efficacy compared to wrfarin. The possible anticoagulation mechanism of blood-quickening and stasis-transforming medicinal may contain intrinsic, extrinsic and common pathway. In conclusion, blood-quickening and stasis-transforming medicinal, whether single herb or formula composotion, all have eaxctly anticoagulative efficacy. They should be effective, safe, and convenient anticoagulant agents in clinical anticoagulative therapy.
In clinical study, it was proved that blood-quickening and stasis-transforming medicinal fomula, Complex Thrombolysis Capsual had siminar efficacy as asprin in anticoagulant therapy to the CHD patients. Complex Thrombolysis Capsual was superior to the asprin to relieve the symptom of CHD patients. This may be relevant to its anticoagulation although its efficacy was mild. Therefor Complex Thrombolysis Capsual may be as a alternative to asprin for patients who can not tolerate it. It will point out that blood-quickening and stasis-transforming medicinal have safe anticoagulative efficacy, and may be as the substitude of the western anticoagulative medicinal to some extent.
抗凝治疗对于心血管病的防治有着重要的意义。现有抗凝治疗主要以西药为主,包括肝素、华法林、水蛭素等。其中肝素为注射剂,不便长期抗凝；华法林作为主要的口服剂广泛应用于心血管抗凝治疗中,但其药物安全窗窄,需要临床检测的特点直接带来了临床依从性差。而临床中,活血化瘀中药在抗凝治疗方面已经广为应用,大多为口服,具有服用方便、相对安全、副作用较小、病人依从性好的特点,但缺乏系统评价这类中药的抗凝效果。
目的
总结活血化瘀中药在心血管疾病抗凝治疗中的作用,结合实验确认其抗凝作用,以及抗凝血酶活性；评价不同药物配伍的抗凝效果,为临床抗凝治疗提供依据。
方法
实验研究
1.抗凝血酶效价实验
分别取含有0.5%纤维蛋白原的Tris-HCl缓冲液0.2mL,于室温下滴于滴定板上,加入50μL待测液充分混匀,滴加5μL凝血酶(40U／mL)迅速匀散,同时计时,用针尖拨动溶液,当有丝状凝结物被针挑起时,记下时间,其所需凝血酶,用量即为V1,若lmin内未凝结,则以分钟为间隔继续滴加,每次2μL,记下针尖能挑起丝状凝结时的消耗凝血酶的体积。用同法以蒸馏水作对照。按下式计算每克供试品抗凝血酶活性单位AT-U。
式中：U—每1g药材抗凝血酶活性效价,单位U／g；
C1—凝血酶溶液的浓度,U／mL；该实验中为40U／mL；
C2—供试品溶液的浓度,g／mL；该实验中为lg／mL
V1—消耗凝血酶溶液的体积,mL；
V2—供试品溶液的加入量,mL；该实验中为0.05mL；
W—取样量。该实验中为0.2mL。
中和一个单位的凝血酶的量,为一个抗凝血酶活性单位。
2.药物配伍抗凝血实验
选取抗凝血酶效价实验中抗凝血酶活性最强的三味中药,A、B、C,组成A+B、A+C、B+C、A+B+C四种配伍；阳性对照药为华法林钠片,2.5mg／片。
采用完全随机对照设计,将60只wistar大鼠分为空白组、阳性对照组,A+B、A+C、B+C、A+B+C四个配伍组,共6组中,每组10只。空白组给予蒸馏水；阳性对照华法林组给予成人剂量0.1mg/kg的4倍(0.4 mg/kg)的华法林,溶于蒸馏水；试验药物各组按成人常用量8倍折合成小鼠用量2g／kg／d给药。各组均灌胃给药,每日1次,连续7天,末次给药后1h,自腹主动脉采血测定凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、纤维蛋白原含量(FIB)。
统计处理：采用SPSS13.0软件,运用多样本均数比较的方差分析(analysis of variance, ANOVA)的方法,比较各处理组之间的差异性；多个样本均数间的多重比较(multiple comparison)的方法,比较各处理组与空白组、各处理组两两之间的差异性。
临床研究
本研究选取2009年1月至2009年12月,在广东省中医院心脏中心就诊,根据WHO1979年关于冠心病诊断标准,确诊为冠心病,并且属于慢性心肌缺血综合症者共60例。完全随机对照将他们分为治疗组,对照组,每组30例。治疗组给予中成药复方血栓通胶囊3粒,tid,连续应用30天；对照组：给予拜阿司匹林100mg,qd,连续应用30天；两组均给予扩冠等常规治疗。各组分别于纳入试验当天(服药前)、服药后第31天分别采外周抗凝血送检PT、TT、APTT、FIB；并记录症状疗效评分表。
结果
实验研究
所有药物组抗凝血酶活性单位AT-U均显著高于空白组；按AT-U从大到小顺序排列,依次为土鳖、丹参、赤芍、僵蚕、水蛭、地龙、川芎、红花。其中,分别与水蛭比较,土鳖、丹参、赤芍、川芎的抗凝血酶活性单位AT-U大于水蛭,红花小于水蛭,而僵蚕、地龙则无显著差异;分别与僵蚕比较,土鳖、丹参、赤芍大于僵蚕,地龙、川芎、红花小于僵蚕,水蛭无显著差异；分别与地龙比较,水蛭、僵蚕、土鳖、丹参、赤芍大,川芎、红花无差异；与土鳖比较,各组均显著小于它；与丹参比较,土鳖大于它,水蛭、僵蚕、地龙、川芎、红花小,赤芍无显著差异；与川芎比较,水蛭、僵蚕、土鳖、丹参、赤芍均大于它,地龙、红花无显著差异；与赤芍比较,土鳖大于它,水蛭、僵蚕、地龙、川芎、红花小于它,丹参无显著差异；与红花比较,水蛭、僵蚕、土鳖、丹参、赤芍均大于它,地龙、川芎无显著差异。抗凝作用最强的前三个药物为土鳖、丹参、赤芍。
土鳖、赤芍、丹参三者不同的配伍用药,对大鼠TT、PT、APTT均有不同的影响,差异有显著性意义(P<0.05)；其中华法林与四种中药配伍方式均有延长大鼠的PT、TT效果(P<0.05)；与华法林阳性对照组比较,四种中药配伍延长PT、TT的作用差异无显著性意义(P>0.05)；四种中药配伍彼此之间两两比较,对PT、TT的影响无显著差异(P<0.05)；与空白组、华法林、以及其它三种配伍比较,土鳖A+丹参B+赤芍C明显延长APTT(P<0.05)。空白组、华法林组、土鳖A+丹参B、土鳖A+赤芍C、丹参B+赤芍C、土鳖A+丹参B+赤芍C对FIB的影响无显著性差异。临床研究
治疗组、对照组两组患者一般情况差异无统计学意义(>0.05),具有可比性。治疗前两组间PT、TT、APTT、FIB比较无显著差异(p>0.05);治疗后和治疗前同组比较,治疗组与对照组的PT、TT均较治疗前有所升高(p<0.05),但都尚在正常值范围内；治疗后两组间PT、TT、APTT、FIB比较无显著差异(p>0.05),均值均在正常范围内。治疗前两组间中医症状评分值无显著差异(p>0.05)；治疗前后比较,治疗组、对照组症状评分均有下降,差异有显著性(p<0.05);治疗后,两组间比较,治疗组症状评分值下降更显著(p<0.05)。
结论
现在及今后抗凝治疗的热点在于发现直接的凝血酶抑制剂,水蛭素已经被证实具有强大的直接抑制凝血酶作用。在本研究中,我们发现活血化瘀中药中,除水蛭外,土鳖、丹参、赤芍、僵蚕、地龙、川芎、红花也含有凝血酶的直接抑制成分,其中以土鳖、丹参、赤芍抗凝血酶活性最强。
体外实验中,活血化瘀药物土鳖、丹参、赤芍、僵蚕、水蛭、地龙、川芎、红花均有确切抗凝作用；在大鼠体内抗凝实验中,不同配伍土鳖A+丹参B、土鳖A+赤芍C、丹参B+赤芍C、土鳖A+丹参B+赤芍C,四种方式具有与华法林同样的抗凝效果,并且抗凝机制涉及环节更多,涵盖了凝血过程的内源性、外源性以及共同途径。所以认为活血化瘀中药单味药、配伍组合均有确切抗凝效果,活血化瘀中药可以作为临床抗凝治疗中有效、安全、方便的制剂。
活血化瘀中成药复方血栓通胶囊在治疗“冠心病”属于慢性心肌缺血综合症者时,与拜阿司匹林一样具有改善临床症状的功效,且比拜阿司匹林效果更为显著。其具有一定抗凝作用,这种抗凝作用是温和的,仅引起PT、TT轻微升高,并未引起凝血指标超出正常值；这种抗凝作用与拜阿司匹林的抗凝作用相比,无显著差异,所以对于属于慢性心肌缺血综合症的冠心病患者,如果不能耐受阿司匹林,其二级预防可以选用复方血栓通胶囊。
Objectives
To summarize the clinical efficacy of blood-quickening and stasis-transforming medicinal on anticoagulative therapy of heartvascular disease. By experiment, to confirm and assess the anticoagulative efficacy of them, and provide some evidence for clinical therapy.
Methods
Experimental study
1. Antithrombin bioactivity experiment
First, eight varieties of Traditional Chinese Medicinal, included leech, silkworm, earthworm, wingless cockroach, salvia, ligusticum, red peony and saffron had been distilled as liquid test sample medicine which oncentration is equivalent to lg/L crude drug. Then respectively, after 0.2mL Tris-HCl buffer contained 0.5% fibrinogen was dripped on microtitration plate and 50μL test sample was mixed into it, thrombin which concentration is 40μ/mL would be titrated into the test sample step by step. Simultaneously, it was timed. The consumed dosage of thrombin would be recorded ultimatily when some filiform coagulum had been seeked out by needle, and converted into the antithrombin unit per gram (AT-U) of the tset sample as distilled water was the control.
Formula:AT-U=C1V1/C2V2W
U:thrombin activity unit per gram, U/g; C1:the concentration of thrombin solution, U/mL, it is 40U/mL in this experiment; C2:the concentration of test sample, g/mL, it is lg/mL in this experiment; V1:the consumed thrombin solution volume, mL; V2:the added volume of test sample, mL, it is 0.05mL in this experiment; W:the added Tris-HCl buffer volume, it is 0.2mL in this experiment.
It is an antithrombin unit when the consumed thrombin solution volume counteract a unit thrombin 2.Anticoagulative experiment about the formula composition of Trditional Chinese Medicine in rat model
There were three varieties of Traditional Chinese Medicine selected from the former eight varieties that had potent AT-U. They were labled A, B and C, and combined each other as four groups, A+B、A+C、B+C、and A+B+C. Walfarin was the positive controlled drug.
By randomised controlled method, 60 Wistar rices were divided into 6 groups: placebo group, positive drug controlled group, A+B、A+C、B+C、and A+B+C four experimental groups. Every group had 10 rices. Distilled water was fed in placebo group. In positive group, Warfarin was dissolved in distilled water and fed to rices with fourfold adult dosage,0.4 mg/kg. In every experimental group, the dosage was eightfold adult's dosage,2g/kg/d. All test drug had been fed to rices by intragastric administration once every day for 7 days. Then,3mL blood was taken from abdominal aorta of rice after the last feeding 1 hour. Prothrombin time(PT), active partial thromboplastin time(APTT), thrombin time(TT) and fibrinogen(FIB) were tested.
Statistics:By SPSS13.0 software, the difference between groups would be tested through analysis of variance(ANOVA) method, and the difference between the dealed groups and the blank group, the dealded groups each other would be tested through multiple comparison method.
Clinical study
Between Janury 2009 to December 2009 in Guangdong Province Tradtional Chinese Medicine(TCM) Hospital,60 cases patients of Coronary Heart Disease(CHD) diagnosised on 1979 WHO standard were randomizedly divided into two group:treatment group and control group. Complex Thrombolysis Capsual was adminstrated to patients in treatment group and asprin was dosed in control group for the following 30 days. Blood sample were taken from peripheral blood of patients to test PT, TT, APTT, FIB and a symptom questionnaire was filled at first day and at 31th day respectively.
Result Experimental study
All drug groups'thrombin activity unit (AT-U) are significantly higher than the placebo group. They are wingless cockroach, salvia, red peony, silkworm, leech, earthworm, ligusticum, and saffron respectively based on the gradation of their AT-U value from high to low. Be compared to leech, the AT-U value of wingless cockroach, salvia, red peony and ligusticum are higher significantly than its; saffron's AT-U value is lower and silkworm earthworm's are no difference. Be compared to silkwom respectively, wingless cockroach, salvia and red peony's AT-U value are higher; earthworm, ligusticum, and saffron's AT-U value are lower; leech's is no difference. Be compared to earthworm respectively, beech, silkworm, wingless cockroach, salvia and red peony's AT-U value are higher; ligusticum and saffron's are no difference. Be compared to wingless cockroach, the other herbs'AT-U value are lower. Be compared to salvia, wingless cockroach's AT-U value is higher; beech, silkworm, earthworm, ligusticum and saffron's AT-U value are lower; and red peony's is no difference. Be compared to ligusticum, beech, silkworm, wingless cockroach, salvia and red peony's AT-U value are higher; and earthworm and saffron's are no difference. Be compared to red peony, the AT-U value of wingless cockroach is higher; beech, silkworm, earthworm, ligusticum and saffron's AT-U value of are lower; and salvia's is no difference. Be compared to saffron, the AT-U value of beech, silkworm, wingless cockroach, salvia and red peony are higher; earthworm and ligusticum's are no difference. As a whole, the potent three herbs of AT-U value are wingless cockroach, slvia and red peony.
The difffrent formula composition of wingless cockroach, slvia and red peony had inordinately influence to TT, PT, APTT of rice. The difference has statistical significance, P<0.05. Warfarin and four types of composition of herbs all can prolong the PT and TT of rice significantly, p<0.05. Be compared to Warfarin positive group, the potency of four herbs composition group have no difference in prolonging PT and TT, p>0.05. There are no difference about PT and TT of rice between the four herbs composition groups while compared each other one by one. Be compared to placebo group, warfarin positive group and the other three herbs group, the wingless cochroach A + salvia B + red peony C group prolonged APTT of rice significantly, p<0.05. There are no significant difference in FIB value of rice between the whole test group each other.
Clinical study
There are no stastic difference in general state between two groups p>0.05. In other words, there are comparability between them. No difference was in PT, TT, APTT and FIB befor treatment, p>0.05; PT and TT in two groups was obviously higher after treatment, p<0.05, but the value was in the normal range. Compared the two groups, there was no significant difference in PT, TT, APTT, FIB between them after treatment, p>0.05. there was no differene in score of TCM symptom questionaire between two groups befor therapy, p>0.05. But after therapy, the score was lower than befor in two groups and the score of treatment group was significant lower than which of control group, p<0.05.
Conclusion
Presently, much emphasis has been placed on the development of direct thrombin inhibitors (DTIs) in anticoagulation therapy field. It is proved that hirudin is the most potent direct thrombin inhibitor. Based on our study, we find that besides beech, there are wingless cockroach, salvia, red peony, silkworm, earthworm, ligusticum and saffron that have some element directly inhibiting thrombin. Among which, wingless cockroach, salvia and red peony have potent thrombin activity significantly.
In vitro animal experiment, the blood-quickening and stasis-transforming medicinal including wingless cockroach, salvia, red peony, silkworm, beech, earthworm, ligusticum and saffron all have exactly anticoagulative efficacy. In vivo rice model anticoagulation experiment, different four formula compositions, wingless cockroach A + salvia B, wingless cockroach A + red peony C, salvia B + red peony C and wingless cockroach A + salvia B + red peony C, have the identical anticoagulative efficacy compared to wrfarin. The possible anticoagulation mechanism of blood-quickening and stasis-transforming medicinal may contain intrinsic, extrinsic and common pathway. In conclusion, blood-quickening and stasis-transforming medicinal, whether single herb or formula composotion, all have eaxctly anticoagulative efficacy. They should be effective, safe, and convenient anticoagulant agents in clinical anticoagulative therapy.
In clinical study, it was proved that blood-quickening and stasis-transforming medicinal fomula, Complex Thrombolysis Capsual had siminar efficacy as asprin in anticoagulant therapy to the CHD patients. Complex Thrombolysis Capsual was superior to the asprin to relieve the symptom of CHD patients. This may be relevant to its anticoagulation although its efficacy was mild. Therefor Complex Thrombolysis Capsual may be as a alternative to asprin for patients who can not tolerate it. It will point out that blood-quickening and stasis-transforming medicinal have safe anticoagulative efficacy, and may be as the substitude of the western anticoagulative medicinal to some extent.
引文
[1]Collins B,Hollidge C. Antithrombotic drug market. Nat Rev Drug Discov, 2003; 2 (1):11-12
[2]J Fenton JW, Villanueva GB, Of osu FA, et al. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis,1991; 21(Suppl 1):S27-S31.
[3]Huhle G, Hofmann U, Song X, et al. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol,1999; 106:195-201.
[4]James S Kalus, Michael F Caron. Novel use for current and future direct thrombin inhibitors:focus on ximelagatran and bivalirudin. Expert Opin. Investig. Drugs,2004; 13(15):465-477
[5]Fareed J, Jeske WP. Small molecule direct antithrombins： argatreban. Best Pract Res Clin Haematol,2004; 17:127-138.
[6]Shapiro SS. Treating thrombosis in the 21st century[J]. N Eng J Med,2003; 349(18):1762-1764
[7]AstraZeneca receives action letter from FDA for ExantaTM (ximelagatran). Available at http://fdaadvisorycommittee.com.
[8]Jawed Fareed, Debra A, Hoppensteadt, etc. Survival of heparins, oral anticoagulants, and aspirin after the 2010. Semin Thromb Hemost,2008; 34:58-73
[9]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005；3(11)：10
[10]王乃利,任静,曲戈霞.活血化瘀类中药复方体外抗凝及纤溶活性研究.沈阳药学院学报,1991；8(2)：117—120
[11]柴志强,魏立,丁钰.复方丹参滴丸干预阿司匹林抵抗的临床试验.实用医药杂志,2008;25(4)：387—389
[12]李涛,耿炳华,王海燕.复方丹参滴丸降脂、抗凝、改善血液流变学作用的实验研究.黑龙江畜牧兽医2000；3：22—23
[13]郝传真,朱建华,戴高中.验方双降散体外抗凝作用探讨.中国中医药信息杂志,2000;7(4)：48
[14]万海同,白海波,杨洁红.养阴方对培养人脐静脉内皮细胞抗凝和纤溶功能的影响.中国中西医结合急救杂志,2001；8(6)：335—337
[15]李华,刘连权.附子泻心汤抗凝作用研究.锦州医学院学报,1996；17(4)：29—30
[16]任慧霞,梁风英.健脾止遗片抗凝抗动脉粥样硬化及改善血液流变学的实验研究.中华临床医药,2004；5(2)：7—8
[17]黎燕峰,张永健,郭鸣放.中风安口服液抗凝抗疲劳的药效学实验研究.河北医科大学学报,2003；24(3)：144—146
[18]刘建东,贺福田,张广增.中药抗凝1号胶囊的临床研究.中西医结合心脑血管病杂志,2004;2(10)：564—565
[19]隋海明,丛海波,王展霖.血管吻合术后中药抗凝作用的临床观察.中医正骨,2005；17(10)：20,22
[20]曲戈霞,王乃利,单云霞等.活血化瘀类中药体外抗凝及纤溶活性筛选实验.沈阳药学院学报,1989；6(1)：16—20
[21]曲戈霞,王乃利,单云霞等.活血化瘀类中药体外抗凝及纤溶活性筛选实验(续).沈阳药学院学报,1991；8(1)：77—78
[22]张明发,沈雅琴,朱自平.辛温(热)合归脾胃经中药药性研究——抗血栓形成和抗凝作用.中国中药杂志,1997；22(11)：691—693
[23]罗承锋.水蛭的药理作用与临床应用.血栓与止血学,2006；12(6)：267—272
[24]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：9.26—31
[25]Edith A, Nancy L, Aimee Chevalier. New Anticoagulant Agents:Direct Thrombin Inhibitors.Clin Geriatr Med,2006; 22:33 — 56
[26]Marcello Di Nisio, Saskia Middeldorp, Harry R. Direct Thrombin Inhibitors. N Engl J Med,2005; 353:1028-40.
[27]Edith A, Nancy L, Aimee Chevalier. New Anticoagulant Agents:Direct Thrombin Inhibitors. Cardio Clin,2008; 26:169-187
[28]郁琴,贺进田,莫炜等.重组双功能水蛭素PLGA微球的制备及其特性.复旦学报：医学版,2006；33(1)：17—23
[29]SHEN Li(沈雳),CHEN Shaoping(陈少萍),CAI Zailong(蔡在龙).Effects of fused hirudin on activity of thrombin and function of platelets.Journal of Medical Colleges of PLA,2005; 20(2):75-78
[30]张艳玲,莫炜,王龙生.重组双功能水蛭素抗凝防栓作用的实验研究.中华手外科杂志,2006；22(2)：106—108
[31]马雪瑛,林成仁,刘志去.重组水蛭素抗凝和抗血栓形成作用的实验研究.中国中医药科技,2004；11(1)：33—35
[32]史小莲,刘俊田,李西宽.水蛭免加热提取物抗血栓、抗凝血作用及作用机理实验研究.中国药理通讯,2003；20(1)：56
[33]张强宗,刘俊田,史小莲.水蛭免加热提取物对高凝动物模型凝血系统及血小板聚集率的影响.中国实验方剂学杂志,2006；12(5)：47—49
[34]顿文,杨立志,周尔风.复方水蛭胶囊药理作用初探.山西医药杂志,1995；24(3)：168—170
[35]肖志杰.水蛭注射液对大白鼠血小板粘附和血小板聚集功能的影响.锦州医学院学报,2004；25(5)：39—40
[36]钟山,崔征,王东.水蛭注射液抗血栓与抗凝血作用.沈阳药科大学学报,2006；23(7)：456—458
[37]吕文海,公素琴,杜征国等.水蛭饮片规格质量的调查及实验研究[J]中国中药杂志,1995；20(11)：665-667
[38]张汉贞,聂诗明,张丽萍.不同食性的水蛭抗凝血酶活性的比较.中药材,1998;21(12)
[39]李文,廖福龙,殷晓杰.七种水蛭抗血小板聚集与抗凝血研究.中药药理与临床,1997；13(5)：32-34
[40]吕文海,丁春红,王琦.水蛭炮制的初步药理研究.中国中药杂志,1994；19(7)：407—409
[41]欧兴长.水蛭素的研究概况.中国药学杂志,1991；26(7)：396
[42]唐本遂,聂诗明,张汉贞.不同因素及给药途径对水蛭制剂抗凝活性的影响.中药材,1999；22(8)：383—384
[43]阎雪莹,张学农,张强.重组水蛭素在大鼠胃肠道中的吸收[J].药学学报,2004；39(1)：77—80
[44]韩玉珉,鹿峪峰,王朝晖等.重组水蛭素十二指肠给药后的抗凝血和抗血栓作用实验研究[J].中华血液学杂志,1999；20(9)：483—484
[45]CEN X, NI J, TAN T, et al. Investigation on recombinant hirudin via oral route[J]. Peptides,2006; 27(4):836—840.
[46]成小蔓,杨辉.口服重组水蛭素抗凝、抗血栓作用的实验研究.中国药业,2005；14(6)：30—31
[47]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：9.20—26
[48]贺石林,彭延古.地龙提取液的抗凝作用与毒性.湖南医科大学学报,1990；15(2)：107—111
[49]李安国,姚龙彪,贺石林.地龙提取液的新型抗凝活性.湖南医科大学学报,1990,15(2)：112—114
[50]何红,车庆明,孙启时.地龙提取物的抗凝血作用.中草药,2007；38(5)：733-735
[51]张大禄,陈百泉.地龙的纤溶、抗凝、溶栓和血流变作用研究.中药材,2003；26(6)：451
[52]龚峻梅,曲宏达,陈素云.地龙及其提取物的药理作用介绍.暨南大学学报(医学版),2000；21(4)：133—135
[53]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：9.179—182
[54]彭延古,李露丹,邓奕辉.僵蚕抗实验性静脉血栓及作用机理的研究..血栓与止 血学,2001；7(3)：104—105
[55]李安国,彭延古,邓常青.僵蚕提取液抗凝活性初步研究.湖南中医学院学报,1992;12(3)：37—40
[56]彭延古,葛金文,邓奕辉.僵蚕抗凝活性成分的研究.湖南中医学院学报,2000；20(4)：18—19
[57]彭延古,雷田香,付灿云.僵蚕抗凝成分ACIBB对实验性静脉血栓形成的影响.中药药理与临床,2007；23(1)：27—29
[58]彭延古,李露丹,雷田香.僵蚕抗凝成分对血小板聚集的抑制效应.血栓与止血学,2007;13(2)：78—79。
[59]彭延古,曾序求,雷田香.僵蚕抗凝成分对内毒素休克伴弥散性血管内凝血大鼠的保护作用研究.中国中西医结合急救杂志,2007；14(2)：80—82
[60]许光明,张前燕,彭延古.僵蚕抗凝血酶诱导血管内皮细胞释放作用的研究.中西医结合心脑血管病杂志,2007；5(9)：837—839
[61]彭延古,许光明,赵建国.僵蚕抗凝活性部位中化学成分的初步研究.中国中医药信息杂志,2008；15(5)：41—43
[62]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社.1999：9.151—155
[63]许俊杰,孟庆棣,佟丽.土鳖虫水提物对大鼠抗凝血的实验研究.第一军医大学学报,1990；10(3)：262—264
[64]周春风,莱萌,王秀华.土鳖虫抗凝血作用研究.长春中医学院学报,1999；15(4)：47。
[65]贺卫和,成细华,徐爱良.土鳖虫提取液对家兔抗凝血作用的实验研究.湖南中医学院学报,2003;23(2)：7—9
[66]王征,陈晓光,吴岩.土鳖虫溶栓酶抗凝血及抗血栓作用的实验研究.中国实验诊断学,2007；11(9)：1143—1145
[67]李友宾,张健,段金廒.土鳖虫与日本医蛭提取物抗凝血酶活性的比较研究.时珍国医国药,2006；17(3)：350—351
[68]郎杰,郑玉光,陈连文.土鳖虫对大鼠抗凝血和促纤溶作用研究.中药药理与临床,2006；22(3、4)：108—109
[69]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社.1999：9.192—194
[70]金伟,王亚威.虻虫抗凝血物质的提取与鉴定.中医药学报,2000;3：58—60
[71]金伟,王亚威.虻虫抗凝血物质的药理研究.中医药信息,2000；3：64—65
[72]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：7.170—186
[73]陈志勇,翁进,李副刚.764—-3对人血小板功能及血管内皮细胞抗凝作用的影响.中国动脉硬化杂志,1994；2(4)：137—139
[74]顾扬洪,张彩英,黄桂秋.丹参和丹参素对牛内皮细胞抗凝和纤溶功能的影响.上 海第二医科大学学报,1990；10(3)：208—212
[75]颜青,蒋锦琪.丹参片对华法令抗凝作用影响.中成药,2008；30(1)：19—21
[76]韩贵俊,汤素芹.华法林和中药丹参、人参等的交互作用的研究进展.中国自然医学杂志,2007；9(5)：453—454
[77]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：2.280—284
[78]齐岩,王智勇,谢敬东.银杏叶的药理作用研究进展.沈阳医学,2006；23(2)：68—69
[79]陈健康,王雷,李珂.银杏黄酮与蚓激酶的抗凝溶栓作用.心肚杂志,2001;13(4)：308—309
[80]潘家祜,蒋樾廉,常建杰.GBE50抗PAF作用与抗凝活性研究.中国药理通讯,2003；20(1)：49
[81]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：3.521—528
[82]王玉琴,马立翌.赤芍对血液凝固、纤溶系统酶活性的影响[J].中西医结合杂志,1990；10(2)：101—102
[83]伍章保,王汀,刘青云.赤芍总苷抗凝血作用机制研究.安徽中医学院学报,2007；26(3)：39—42。
[84]朴田,莫晓燕,林瑞峥.赤芍总苷提取液体外清除自由基和抗凝血活性的研究.中国药房,2007；18(9)：643—646
[85]徐红梅,刘青云,戴敏.赤芍总甙抗血栓作用研究.安徽中医学院学报,2000；19(1)：46—47
[86]李文,殷小杰,廖福龙.六种产地赤芍对大鼠抗凝血及抗血小板聚集作用的比较.
中国实验方剂学杂志,2001；7(6)：30—31
[87]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：5.839—845
[88]甘烦远,郑光植.三七化学成分研究概况(J).中国药学杂志,1992；27(3)：138-143
[89]黄树莲.三七皂甙Rg1对大鼠实验性血栓形成、血小板集聚抑制的研究[J].药学通报,1997；32(1)：18-21
[90]张力跃,江燕,王德斌.三七皂甙、肝素钠和蝮蛇毒纤溶酶组份对凝血系统的作用研究.昆明师范高等专科学校学报,2000；22(4)：31-33
[91]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：5.976—983
[92]李秀才.抗心肌缺血再灌注损伤的中草药研究进展.中国现代应用药学,1998；18(4)：40。
[93]刘加升,胡国华,蒋明伟等.最新临床药物手册.北京：中国科学技术出版杜,1996：88
[94]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：7.763—770
[95]陈文梅,金鸣,李金荣.红花黄色素对羟自由基损伤抗凝血酶Ⅲ的保护作用.心肺血管病杂志,1998；17(3)：215—217
[96]藏宝霞,吴伟,李蔚然.硅胶吸附法制备红花总黄色素抗凝血作用的实验研究.中国药学杂志,2002；37(2)：102—109
[97]谢瑞金,腾小鹏,申庆亮.红花注射液的稳定性研究.时珍国医国药,2001；1(6)：490
[98]陈文梅,金鸣,吴伟等.红花黄色素抑制ffⅡ小板激活因子介导的血小极活化作用的研究.中国药学杂志,2000；35(11)：741
[99]臧宝霞,金鸣,李金荣.羟基红花黄色素A抗凝作用的研究.中草药,2007；38(5)：741—743
[100]柯庆,邓常青,李安国.红花与赤芍的抗凝协同作用.湖南中医学院学报,1993；13(1)：41—43
[101]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：4.610—618
[102]丁红香,倪孔海,邵美娟.葛根素对失血性休克大鼠内皮细胞和抗凝血功能的影响.中国中西医结合急救杂志,2007；14(1)：32—34
[103]罗助荣,盖晓波,郑卫星等.葛根素治疗不稳定型心绞痛及对凝血纤溶活性和内皮功能的影响.中国中西医结合急救杂志,2000；7(2)：105—106.
[104]沈立,高天明,蔡健康.葛根素配合他药治疗慢性肺心病急性期血栓前状态的临床观察.江苏药学与临床研究,2005；13(6)：27—29
[105]许青媛,于利森,张小利.干姜及其主要成分的抗凝作用.中国中药杂志,1991；16(2)：112—113
[106]任青华,蔡生业.炮附子抗体外血栓的研究.齐鲁中医药情报,1991；28(1)：15
[107]毛平,夏卉莉.怀牛膝多糖抗凝血作用实验研究.时珍国医国药,2000;11(12)：1075—1076
[108]邓英君.三棱不同提取物镇痛及抗凝作用研究.时珍国医国药,1999；10(12)：882—883
[109]邱丽颖,王书华,吕莉.麻黄果多糖的抗凝血机制研究.张家口医学院学报,1999；16(1)：3—4
[110]郑一敏,胥秀英,蔡绍皙.牛蒡子苷对血瘀大鼠血液流变学的影响.中国现代应用药学杂志,2006；23(6)：443—446
[111]国家药典委员会.中华人民共和国药典.化学工业出版社.2005年：57.
[112]吕映华,何迎春,杨娟.冠心病心绞痛(气虚血瘀证)症状疗效评分量表的研究.中国临床药理学与治疗学,2008;13(7)：786-791
[113]Fritz Markwardt. Historical Perspective of the Development of Thrombin Inhibitors. Pathophysiol Haemost Thromb,2002; 32(suppl 3):15-22
[114]Fritz Markwardt. Hirudin as alternative anticoagulant-A history review. Seminars in thrombosis and hemostasis,2002; 28(5):405-413
[115]Gotz Nowak, Karsten Schror.Hirudin-the long and stony way from a anticoagulant peptide in the salvia of medical leech to a recombinant drug and beyond a historical piece. Thromb Haemost,2007; 98:116-119
[2]J Fenton JW, Villanueva GB, Of osu FA, et al. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis,1991; 21(Suppl 1):S27-S31.
[3]Huhle G, Hofmann U, Song X, et al. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol,1999; 106:195-201.
[4]James S Kalus, Michael F Caron. Novel use for current and future direct thrombin inhibitors:focus on ximelagatran and bivalirudin. Expert Opin. Investig. Drugs,2004; 13(15):465-477
[5]Fareed J, Jeske WP. Small molecule direct antithrombins： argatreban. Best Pract Res Clin Haematol,2004; 17:127-138.
[6]Shapiro SS. Treating thrombosis in the 21st century[J]. N Eng J Med,2003; 349(18):1762-1764
[7]AstraZeneca receives action letter from FDA for ExantaTM (ximelagatran). Available at http://fdaadvisorycommittee.com.
[8]Jawed Fareed, Debra A, Hoppensteadt, etc. Survival of heparins, oral anticoagulants, and aspirin after the 2010. Semin Thromb Hemost,2008; 34:58-73
[9]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005；3(11)：10
[10]王乃利,任静,曲戈霞.活血化瘀类中药复方体外抗凝及纤溶活性研究.沈阳药学院学报,1991；8(2)：117—120
[11]柴志强,魏立,丁钰.复方丹参滴丸干预阿司匹林抵抗的临床试验.实用医药杂志,2008;25(4)：387—389
[12]李涛,耿炳华,王海燕.复方丹参滴丸降脂、抗凝、改善血液流变学作用的实验研究.黑龙江畜牧兽医2000；3：22—23
[13]郝传真,朱建华,戴高中.验方双降散体外抗凝作用探讨.中国中医药信息杂志,2000;7(4)：48
[14]万海同,白海波,杨洁红.养阴方对培养人脐静脉内皮细胞抗凝和纤溶功能的影响.中国中西医结合急救杂志,2001；8(6)：335—337
[15]李华,刘连权.附子泻心汤抗凝作用研究.锦州医学院学报,1996；17(4)：29—30
[16]任慧霞,梁风英.健脾止遗片抗凝抗动脉粥样硬化及改善血液流变学的实验研究.中华临床医药,2004；5(2)：7—8
[17]黎燕峰,张永健,郭鸣放.中风安口服液抗凝抗疲劳的药效学实验研究.河北医科大学学报,2003；24(3)：144—146
[18]刘建东,贺福田,张广增.中药抗凝1号胶囊的临床研究.中西医结合心脑血管病杂志,2004;2(10)：564—565
[19]隋海明,丛海波,王展霖.血管吻合术后中药抗凝作用的临床观察.中医正骨,2005；17(10)：20,22
[20]曲戈霞,王乃利,单云霞等.活血化瘀类中药体外抗凝及纤溶活性筛选实验.沈阳药学院学报,1989；6(1)：16—20
[21]曲戈霞,王乃利,单云霞等.活血化瘀类中药体外抗凝及纤溶活性筛选实验(续).沈阳药学院学报,1991；8(1)：77—78
[22]张明发,沈雅琴,朱自平.辛温(热)合归脾胃经中药药性研究——抗血栓形成和抗凝作用.中国中药杂志,1997；22(11)：691—693
[23]罗承锋.水蛭的药理作用与临床应用.血栓与止血学,2006；12(6)：267—272
[24]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：9.26—31
[25]Edith A, Nancy L, Aimee Chevalier. New Anticoagulant Agents:Direct Thrombin Inhibitors.Clin Geriatr Med,2006; 22:33 — 56
[26]Marcello Di Nisio, Saskia Middeldorp, Harry R. Direct Thrombin Inhibitors. N Engl J Med,2005; 353:1028-40.
[27]Edith A, Nancy L, Aimee Chevalier. New Anticoagulant Agents:Direct Thrombin Inhibitors. Cardio Clin,2008; 26:169-187
[28]郁琴,贺进田,莫炜等.重组双功能水蛭素PLGA微球的制备及其特性.复旦学报：医学版,2006；33(1)：17—23
[29]SHEN Li(沈雳),CHEN Shaoping(陈少萍),CAI Zailong(蔡在龙).Effects of fused hirudin on activity of thrombin and function of platelets.Journal of Medical Colleges of PLA,2005; 20(2):75-78
[30]张艳玲,莫炜,王龙生.重组双功能水蛭素抗凝防栓作用的实验研究.中华手外科杂志,2006；22(2)：106—108
[31]马雪瑛,林成仁,刘志去.重组水蛭素抗凝和抗血栓形成作用的实验研究.中国中医药科技,2004；11(1)：33—35
[32]史小莲,刘俊田,李西宽.水蛭免加热提取物抗血栓、抗凝血作用及作用机理实验研究.中国药理通讯,2003；20(1)：56
[33]张强宗,刘俊田,史小莲.水蛭免加热提取物对高凝动物模型凝血系统及血小板聚集率的影响.中国实验方剂学杂志,2006；12(5)：47—49
[34]顿文,杨立志,周尔风.复方水蛭胶囊药理作用初探.山西医药杂志,1995；24(3)：168—170
[35]肖志杰.水蛭注射液对大白鼠血小板粘附和血小板聚集功能的影响.锦州医学院学报,2004；25(5)：39—40
[36]钟山,崔征,王东.水蛭注射液抗血栓与抗凝血作用.沈阳药科大学学报,2006；23(7)：456—458
[37]吕文海,公素琴,杜征国等.水蛭饮片规格质量的调查及实验研究[J]中国中药杂志,1995；20(11)：665-667
[38]张汉贞,聂诗明,张丽萍.不同食性的水蛭抗凝血酶活性的比较.中药材,1998;21(12)
[39]李文,廖福龙,殷晓杰.七种水蛭抗血小板聚集与抗凝血研究.中药药理与临床,1997；13(5)：32-34
[40]吕文海,丁春红,王琦.水蛭炮制的初步药理研究.中国中药杂志,1994；19(7)：407—409
[41]欧兴长.水蛭素的研究概况.中国药学杂志,1991；26(7)：396
[42]唐本遂,聂诗明,张汉贞.不同因素及给药途径对水蛭制剂抗凝活性的影响.中药材,1999；22(8)：383—384
[43]阎雪莹,张学农,张强.重组水蛭素在大鼠胃肠道中的吸收[J].药学学报,2004；39(1)：77—80
[44]韩玉珉,鹿峪峰,王朝晖等.重组水蛭素十二指肠给药后的抗凝血和抗血栓作用实验研究[J].中华血液学杂志,1999；20(9)：483—484
[45]CEN X, NI J, TAN T, et al. Investigation on recombinant hirudin via oral route[J]. Peptides,2006; 27(4):836—840.
[46]成小蔓,杨辉.口服重组水蛭素抗凝、抗血栓作用的实验研究.中国药业,2005；14(6)：30—31
[47]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：9.20—26
[48]贺石林,彭延古.地龙提取液的抗凝作用与毒性.湖南医科大学学报,1990；15(2)：107—111
[49]李安国,姚龙彪,贺石林.地龙提取液的新型抗凝活性.湖南医科大学学报,1990,15(2)：112—114
[50]何红,车庆明,孙启时.地龙提取物的抗凝血作用.中草药,2007；38(5)：733-735
[51]张大禄,陈百泉.地龙的纤溶、抗凝、溶栓和血流变作用研究.中药材,2003；26(6)：451
[52]龚峻梅,曲宏达,陈素云.地龙及其提取物的药理作用介绍.暨南大学学报(医学版),2000；21(4)：133—135
[53]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：9.179—182
[54]彭延古,李露丹,邓奕辉.僵蚕抗实验性静脉血栓及作用机理的研究..血栓与止 血学,2001；7(3)：104—105
[55]李安国,彭延古,邓常青.僵蚕提取液抗凝活性初步研究.湖南中医学院学报,1992;12(3)：37—40
[56]彭延古,葛金文,邓奕辉.僵蚕抗凝活性成分的研究.湖南中医学院学报,2000；20(4)：18—19
[57]彭延古,雷田香,付灿云.僵蚕抗凝成分ACIBB对实验性静脉血栓形成的影响.中药药理与临床,2007；23(1)：27—29
[58]彭延古,李露丹,雷田香.僵蚕抗凝成分对血小板聚集的抑制效应.血栓与止血学,2007;13(2)：78—79。
[59]彭延古,曾序求,雷田香.僵蚕抗凝成分对内毒素休克伴弥散性血管内凝血大鼠的保护作用研究.中国中西医结合急救杂志,2007；14(2)：80—82
[60]许光明,张前燕,彭延古.僵蚕抗凝血酶诱导血管内皮细胞释放作用的研究.中西医结合心脑血管病杂志,2007；5(9)：837—839
[61]彭延古,许光明,赵建国.僵蚕抗凝活性部位中化学成分的初步研究.中国中医药信息杂志,2008；15(5)：41—43
[62]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社.1999：9.151—155
[63]许俊杰,孟庆棣,佟丽.土鳖虫水提物对大鼠抗凝血的实验研究.第一军医大学学报,1990；10(3)：262—264
[64]周春风,莱萌,王秀华.土鳖虫抗凝血作用研究.长春中医学院学报,1999；15(4)：47。
[65]贺卫和,成细华,徐爱良.土鳖虫提取液对家兔抗凝血作用的实验研究.湖南中医学院学报,2003;23(2)：7—9
[66]王征,陈晓光,吴岩.土鳖虫溶栓酶抗凝血及抗血栓作用的实验研究.中国实验诊断学,2007；11(9)：1143—1145
[67]李友宾,张健,段金廒.土鳖虫与日本医蛭提取物抗凝血酶活性的比较研究.时珍国医国药,2006；17(3)：350—351
[68]郎杰,郑玉光,陈连文.土鳖虫对大鼠抗凝血和促纤溶作用研究.中药药理与临床,2006；22(3、4)：108—109
[69]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社.1999：9.192—194
[70]金伟,王亚威.虻虫抗凝血物质的提取与鉴定.中医药学报,2000;3：58—60
[71]金伟,王亚威.虻虫抗凝血物质的药理研究.中医药信息,2000；3：64—65
[72]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：7.170—186
[73]陈志勇,翁进,李副刚.764—-3对人血小板功能及血管内皮细胞抗凝作用的影响.中国动脉硬化杂志,1994；2(4)：137—139
[74]顾扬洪,张彩英,黄桂秋.丹参和丹参素对牛内皮细胞抗凝和纤溶功能的影响.上 海第二医科大学学报,1990；10(3)：208—212
[75]颜青,蒋锦琪.丹参片对华法令抗凝作用影响.中成药,2008；30(1)：19—21
[76]韩贵俊,汤素芹.华法林和中药丹参、人参等的交互作用的研究进展.中国自然医学杂志,2007；9(5)：453—454
[77]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：2.280—284
[78]齐岩,王智勇,谢敬东.银杏叶的药理作用研究进展.沈阳医学,2006；23(2)：68—69
[79]陈健康,王雷,李珂.银杏黄酮与蚓激酶的抗凝溶栓作用.心肚杂志,2001;13(4)：308—309
[80]潘家祜,蒋樾廉,常建杰.GBE50抗PAF作用与抗凝活性研究.中国药理通讯,2003；20(1)：49
[81]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：3.521—528
[82]王玉琴,马立翌.赤芍对血液凝固、纤溶系统酶活性的影响[J].中西医结合杂志,1990；10(2)：101—102
[83]伍章保,王汀,刘青云.赤芍总苷抗凝血作用机制研究.安徽中医学院学报,2007；26(3)：39—42。
[84]朴田,莫晓燕,林瑞峥.赤芍总苷提取液体外清除自由基和抗凝血活性的研究.中国药房,2007；18(9)：643—646
[85]徐红梅,刘青云,戴敏.赤芍总甙抗血栓作用研究.安徽中医学院学报,2000；19(1)：46—47
[86]李文,殷小杰,廖福龙.六种产地赤芍对大鼠抗凝血及抗血小板聚集作用的比较.
中国实验方剂学杂志,2001；7(6)：30—31
[87]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：5.839—845
[88]甘烦远,郑光植.三七化学成分研究概况(J).中国药学杂志,1992；27(3)：138-143
[89]黄树莲.三七皂甙Rg1对大鼠实验性血栓形成、血小板集聚抑制的研究[J].药学通报,1997；32(1)：18-21
[90]张力跃,江燕,王德斌.三七皂甙、肝素钠和蝮蛇毒纤溶酶组份对凝血系统的作用研究.昆明师范高等专科学校学报,2000；22(4)：31-33
[91]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：5.976—983
[92]李秀才.抗心肌缺血再灌注损伤的中草药研究进展.中国现代应用药学,1998；18(4)：40。
[93]刘加升,胡国华,蒋明伟等.最新临床药物手册.北京：中国科学技术出版杜,1996：88
[94]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：7.763—770
[95]陈文梅,金鸣,李金荣.红花黄色素对羟自由基损伤抗凝血酶Ⅲ的保护作用.心肺血管病杂志,1998；17(3)：215—217
[96]藏宝霞,吴伟,李蔚然.硅胶吸附法制备红花总黄色素抗凝血作用的实验研究.中国药学杂志,2002；37(2)：102—109
[97]谢瑞金,腾小鹏,申庆亮.红花注射液的稳定性研究.时珍国医国药,2001；1(6)：490
[98]陈文梅,金鸣,吴伟等.红花黄色素抑制ffⅡ小板激活因子介导的血小极活化作用的研究.中国药学杂志,2000；35(11)：741
[99]臧宝霞,金鸣,李金荣.羟基红花黄色素A抗凝作用的研究.中草药,2007；38(5)：741—743
[100]柯庆,邓常青,李安国.红花与赤芍的抗凝协同作用.湖南中医学院学报,1993；13(1)：41—43
[101]胡熙民,张文康,宋立人等.中华本草.上海科学技术出版社,1999：4.610—618
[102]丁红香,倪孔海,邵美娟.葛根素对失血性休克大鼠内皮细胞和抗凝血功能的影响.中国中西医结合急救杂志,2007；14(1)：32—34
[103]罗助荣,盖晓波,郑卫星等.葛根素治疗不稳定型心绞痛及对凝血纤溶活性和内皮功能的影响.中国中西医结合急救杂志,2000；7(2)：105—106.
[104]沈立,高天明,蔡健康.葛根素配合他药治疗慢性肺心病急性期血栓前状态的临床观察.江苏药学与临床研究,2005；13(6)：27—29
[105]许青媛,于利森,张小利.干姜及其主要成分的抗凝作用.中国中药杂志,1991；16(2)：112—113
[106]任青华,蔡生业.炮附子抗体外血栓的研究.齐鲁中医药情报,1991；28(1)：15
[107]毛平,夏卉莉.怀牛膝多糖抗凝血作用实验研究.时珍国医国药,2000;11(12)：1075—1076
[108]邓英君.三棱不同提取物镇痛及抗凝作用研究.时珍国医国药,1999；10(12)：882—883
[109]邱丽颖,王书华,吕莉.麻黄果多糖的抗凝血机制研究.张家口医学院学报,1999；16(1)：3—4
[110]郑一敏,胥秀英,蔡绍皙.牛蒡子苷对血瘀大鼠血液流变学的影响.中国现代应用药学杂志,2006；23(6)：443—446
[111]国家药典委员会.中华人民共和国药典.化学工业出版社.2005年：57.
[112]吕映华,何迎春,杨娟.冠心病心绞痛(气虚血瘀证)症状疗效评分量表的研究.中国临床药理学与治疗学,2008;13(7)：786-791
[113]Fritz Markwardt. Historical Perspective of the Development of Thrombin Inhibitors. Pathophysiol Haemost Thromb,2002; 32(suppl 3):15-22
[114]Fritz Markwardt. Hirudin as alternative anticoagulant-A history review. Seminars in thrombosis and hemostasis,2002; 28(5):405-413
[115]Gotz Nowak, Karsten Schror.Hirudin-the long and stony way from a anticoagulant peptide in the salvia of medical leech to a recombinant drug and beyond a historical piece. Thromb Haemost,2007; 98:116-119
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |